| Danielle Enders, OTR | |
|
3044 Due West Rd, Dallas, GA 30157-2125 | |
| (208) 814-7950 | |
| Not Available |
| Full Name | Danielle Enders |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 3044 Due West Rd, Dallas, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235710377 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT-2366 (Idaho) | Secondary |
| 225X00000X | Occupational Therapist | OT008261 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Danielle Enders, OTR 3044 Due West Rd, Dallas, GA 30157-2125 Ph: () - | Danielle Enders, OTR 3044 Due West Rd, Dallas, GA 30157-2125 Ph: (208) 814-7950 |
News Archive
Neogenix Oncology announced today that its registration statement on Form 10 as amended, filed with the Securities and Exchange Commission (SEC) to register its common stock pursuant to Section 12(g) of the Securities Exchange Act of 1934, has become effective. The Form 10 includes a description of the business of the company, management's discussion and analysis of financial condition, financial statements for the past two years and the first quarter of 2010, as well as other legal and financial disclosures such as risk factors.
Lucideon will host a webinar titled ‘Cleaning Validation of Reusable Medical Devices' on the 9th June at 15:00hrs, 10:00hrs (EST).
A social media post, which in April was shared widely on Facebook and made appearances on a conservative online discussion forum, asserts that former President Barack Obama signed legislation that caused companies to manufacture medical devices overseas, including items essential for the current coronavirus pandemic.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.
› Verified 2 days ago
Helping Hands Therapeutic Services, Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 19 Walnut Creek Ln, Dallas, GA 30157 Phone: 770-310-0510 | |
Mckenna Farms Therapy Services Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3044 Due West Rd, Dallas, GA 30157 Phone: 770-443-9672 Fax: 770-505-3595 | |
Autumn T Megan, MSOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3044 Due West Road, Dallas, GA 30157 Phone: 177-044-3967 | |
Jeanna Sommer, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3044 Due West Rd, Dallas, GA 30157 Phone: 770-443-9672 Fax: 770-505-3595 | |
Sarah Bolt, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3044 Due West Rd, Dallas, GA 30157 Phone: 770-443-9672 | |
Veronica Cristina Garza, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3044 Due West Rd, Dallas, GA 30157 Phone: 770-443-9672 | |
Hannah L Stern, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3044 Due West Rd, Dallas, GA 30157 Phone: 770-443-9672 |